Daratumumab combination prolongs myeloma survival

MeSH terms

• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / therapeutic use*
• Antineoplastic Agents, Immunological / adverse effects
• Antineoplastic Agents, Immunological / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Clinical Trials, Phase III as Topic
• Disease-Free Survival
• Humans
• Multiple Myeloma / drug therapy*
• Multiple Myeloma / immunology
• Multiple Myeloma / mortality
• Multiple Myeloma / pathology
• Randomized Controlled Trials as Topic
• Recurrence
• Time Factors
• Treatment Outcome